Table I.
Patient characteristics and correlations between patient sex and various clinicopathological variables.
| Variables | n (%) | Male, n (%) | Female, n (%) | P-value |
|---|---|---|---|---|
| No. of patients | 1,169 (100.0) | 634 (54.3) | 535 (45.7) | |
| Age, years | 0.034 | |||
| <50 | 531 (45.4) | 270 (42.6) | 261 (48.8) | |
| ≥50 | 638 (54.6) | 364 (57.4) | 274 (51.2) | |
| Site of lesion | 0.0001 | |||
| Trunk | 659 (58.4) | 402 (66.7) | 257 (49.0) | |
| Extremities | 469 (41.6) | 201 (33.3) | 268 (51.0) | |
| Histology 1 | 0.698 | |||
| Superficial spreading | 405 (48.7) | 216 (49.3) | 189 (48.0) | |
| Others | 427 (51.3) | 222 (50.7) | 205 (52.0) | |
| Histology 2 | 0.005 | |||
| Nodular | 254 (30.5) | 152 (34.7) | 102 (25.8) | |
| Others | 580 (69.5) | 286 (65.3) | 294 (74.2) | |
| Clark's level | 0.004 | |||
| I–III | 290 (32.1) | 137 (28.0) | 153 (36.9) | |
| IV–V | 614 (67.9) | 352 (72.0) | 262 (63.1) | |
| Breslow's thickness, mm | 0.0001 | |||
| <2 | 311 (35.5) | 134 (28.2) | 177 (44.1) | |
| ≥2 | 565 (64.5) | 341 (71.8) | 224 (55.9) | |
| Neurotropism | 0.410 | |||
| Present | 23 (4.4) | 14 (5.1) | 9 (3.6) | |
| Absent | 499 (95.6) | 260 (94.9) | 239 (96.4) | |
| Mitotic rate, n/mm2 | 0.241 | |||
| ≤3 | 436 (57.9) | 226 (55.9) | 210 (60.2) | |
| >3 | 317 (42.1) | 178 (44.1) | 139 (39.8) | |
| Ulceration | 0.0001 | |||
| Present | 429 (54.3) | 257 (60.2) | 172 (47.4) | |
| Absent | 361 (45.7) | 170 (39.8) | 191 (52.6) | |
| Vertical growth phase | 0.065 | |||
| Present | 422 (89.4) | 227 (91.9) | 195 (86.7) | |
| Absent | 50 (10.6) | 20 (8.1) | 30 (13.3) | |
| LVI | 0.302 | |||
| Present | 80 (11.3) | 47 (12.5) | 33 (10.0) | |
| Absent | 627 (88.7) | 330 (87.5) | 297 (90.0) | |
| TIL | 0.519 | |||
| Absent | 264 (35.2) | 138 (34.2) | 126 (36.4) | |
| Present | 486 (64.8) | 266 (65.8) | 220 (63.6) | |
| Regression | 0.032 | |||
| Present | 169 (25.3) | 104 (28.7) | 65 (21.4) | |
| Absent | 498 (74.7) | 259 (71.3) | 239 (78.6) | |
| Underlying precursor lesion | 0.924 | |||
| Present | 176 (31.5) | 90 (31.4) | 86 (31.7) | |
| Absent | 382 (68.5) | 197 (68.6) | 185 (68.3) | |
| BRAF | 0.493 | |||
| Negative | 39 (56.5) | 27 (54.0) | 12 (63.2) | |
| Positive | 30 (43.5) | 23 (46.0) | 7 (36.8) | |
| Lymph node involvement (node 1) | 0.047 | |||
| Yes | 374 (50.1) | 223 (53.3) | 151 (46.0) | |
| No | 372 (49.9) | 195 (46.7) | 177 (54.0) | |
| No. of involved lymph nodes (node 2) | 0.732 | |||
| 1 | 211 (57.0) | 125 (56.3) | 86 (58.1) | |
| ≥2 | 159 (43.0) | 97 (43.7) | 62 (41.9) | |
| Metastasis (metastasis 1) | 0.003 | |||
| Present | 131 (11.2) | 87 (13.7) | 44 (8.2) | |
| Absent | 1,037 (88.8) | 546 (86.3) | 491 (91.8) | |
| Type of metastasis (metastasis 2) | 0.198 | |||
| M1a-b | 41 (31.3) | 24 (27.6) | 17 (38.6) | |
| M1c | 90 (68.7) | 63 (72.4) | 27 (61.4) | |
| Recurrence | 0.0001 | |||
| Yes | 360 (30.8) | 225 (35.5) | 135 (25.3) | |
| No | 808 (69.2) | 409 (64.5) | 399 (74.7) |
Bold print indicates statistical significance. LVI, lymphovascular invasion; TIL, tumor-infiltrating lymphocytes.